Uncategorized
Trump’s Tariff Exemptions Include Semiconductors, Pharmaceuticals, Oil And More
President Donald Trump on Wednesday announced a slew of tougher-than-anticipated tariffs, but there are some notable exemptions to the steep levies. Here’s a look at which products and sectors are excluded from the reciprocal tariffs: read more
Kohl’s Shares Tumble, But Analyst Sees Promise In New CEO’s Strategy
Kohl’s Corp (KSS) stock tanks after announcing store closures. New CEO plans turnaround with focus on merchandising and pricing strategies. Latest Ratings for KSS Date Firm Action From To Mar 2022 Telsey Advisory Group Maintains Market Perform Mar 2022 Credit Suisse Maintains Neutral Feb 2022 Gordon Haskett Downgrades Buy Accumulate View More Analyst Ratings for…
Trump Auto Tariffs Could Up Car Prices By $15K, Analyst Calls It ‘Pure Chaos’
“This 25% auto tariff number is hard to digest,” Dan Ives says, predicting continued downward pressure on GM and Ford. read more
Samsung’s China Chip Pivot Gains Steam With 54% Export Surge Amid US Market Struggles
Samsung Electronics turns to Chinese tech groups to boost semiconductor division after struggling to secure US customers. Exports to China rise 54% amid US sanctions. read more
AI-Powered Pizza? Papa Johns Taps Google Cloud For Smarter Orders
Papa Johns (NASDAQ: PZZA) is teaming up with Google Cloud (NASDAQ: GOOGL) to boost the pizza-ordering experience with AI-driven personalization, predictive analytics, and automation. The partnership aims to enhance customer engagement, optimize delivery logistics, and streamline operations through advanced machine learning and data analysis. read more
Qualcomm Expands AI Ambitions With Acquisition of VinAI’s Generative AI Division
Qualcomm’s acquisition of MovianAI, a generative AI division of VinAI, will strengthen its R&D and boost its position in 5G, AI, IoT and automotive. read more
BeiGene Discontinues Lung Cancer Drug Study After Interim Data Showed Limited Survival Benefit
BeiGene ends its Phase 3 lung cancer trial for ociperlimab after a futility analysis. No new safety concerns were found, and study results will be shared later. read more